NEWS

NEWS

Sponsored Session at CBI Annual Meeting 2026: “How Agentic AI Is Transforming Drug Discovery Research”

On October 28, 2026, Xeureka hosted a sponsored session at the CBI Annual Meeting 2026 entitled “How Agentic AI Is Transforming Drug Discovery Research: The Evolution of Research Processes, Organizations, and the Tokyo-1 Community.”

The session drew a large audience, with standing room only, reflecting strong interest in generative AI and AI agents for drug discovery, as well as the growing focus on how these technologies can be integrated into day-to-day research.

The session opened with our introduction to Tokyo-1. Since its launch in 2024, Tokyo-1 has provided high-performance GPU computing infrastructure while also fostering a collaborative community that reaches across organizational boundaries. Through initiatives such as working groups and hackathons, Tokyo-1 has promoted knowledge sharing and the hands-on exploration of emerging technologies among participating companies.

In the first half of the session, speakers from Tokyo-1 participating companies—Masakuni Kurono of Ono Pharmaceutical, Takunori Yasuda of Daiichi Sankyo, Toshiyuki Ohfusa of Astellas Pharma, and Keishi Akada of Eisai—presented their latest initiatives in areas including AI research assistants and agents, structure prediction technologies, and researcher-driven AI applications. Across the presentations, one theme stood out: the focus is increasingly shifting from “how to use AI” to “how AI can transform the way research itself is conducted.”

The second half featured a panel discussion, moderated by Kazuya Nagaoka of Astellas Pharma, centered on the three pillars of Tokyo-1: Community for Co-creation and Collaboration, High-Spec GPU Supercomputers, and Cutting-edge DX Solutions. Panelists exchanged candid views on topics including cross-company knowledge sharing and mutual learning, the research value of having ready access to high-performance GPU resources when needed, and the environment required to enable a broader range of researchers to leverage AI and large-scale computing.

The post-session survey also received highly positive feedback, along with comments expressing interest in Tokyo-1 and expectations for future joint technology development and collaboration.

Going forward, Xeureka will continue working together with Tokyo-1 participating companies to support the evolution of the research environment from “using AI” to “conducting research together with AI.” Through cross-company knowledge sharing and practical collaboration, we aim to contribute to the continued advancement of drug discovery research in Japan.

We would like to extend our sincere appreciation to all the speakers, participants, and everyone who contributed to making this session possible.


BACK